Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004334 | PO / MO |
The patient took Vivotif doses two and three in consecutive days; Case reference number US-BN-2025-001619 is a spontaneous case initially received from a healthcare professional via Communications (reference number: USBAV25-2430) on 30-Sep-2025 and concerns a female patient of unknown age born in 1968. The patient's medical history and concomitant medication details were not provided. On an unspecified date in Sep-2025, the patient took the first dose of Vivotif vaccine (batch number: 3004334 and expiration date: 31-Jul-2026) at an unknown dose (reported as 4 doses series), orally for pre-travel immunization. On an unspecified date in Sep-2025, unknown amount of time after first dose, the patient took the second dose of Vivotif vaccine (batch number: 3004334 and expiration date: 31-Jul-2026) one dose, orally. On an unspecified date, next day after the second dose, the patient took the third dose of Vivotif vaccine (batch number: 3004334 and expiration date: 31-Jul-2026) one dose, orally. (explicitly coded as 'inappropriate schedule of vaccine administered'). *As reported, the reporter advised the patient to continue medication, so skip a day and take the last dose.* At the time of the follow-up report, it was reported that the patient did not experience any adverse event due to Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a health care professional via Bavarian Nordic on 13-Oct-2025: New information included additional patient details and suspect product details. Follow up information received from a health care professional via Bavarian Nordic on 31-Oct-2025: New information included advised how to continue the medication.; Reporter's Comments: This case concerns a female patient of unknown age (born in 1968), as reported, received the third dose of Vivotif, on the next day after the second dose for pre-travel immunization, which is considered as inappropriate schedule of product administered. Inappropriate schedule of product administered is considered as listed per company convention. The patient did not experience any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a female patient of unknown age (born in 1968), as reported, received the third dose of Vivotif, on the next day after the second dose for pre-travel immunization, which is considered as inappropriate schedule of product administered. Inappropriate schedule of product administered is considered as listed per company convention. The patient did not experience any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None